Building Oncology Biomarker Programs using Sequencing & Computational Discovery

Presented by

Michael Ritchie, PhD, MBA, Chief Commercial Officer, Champions Oncology

About this talk

Tumor volume measurements represent a single and superficial dimension of the information that can be collected during a preclinical pharmacology study. Advances in sequencing and computational analytics have provided a new dimension of information that illuminates the cellular dynamics of a given therapeutic response. At Champions Oncology, we deliver innovative end-to-end solutions that accelerate oncology drug development. Our technology enabled end-to-end platforms encompass advanced pharmacology models, robust sequencing services, and cutting-edge bioinformatic analyses. The power of these platforms is in the ability to explore genomic and transcriptomic data assembled from your preclinical studies and explore this data in the context of over 13,000 cancer patients, including thousands of clinical treatment responses not available in any public dataset. In this webinar, case studies will be presented to demonstrate the many different ways to use our newest sequencing and bioinformatics platforms can be used to explore mechanisms of resistance and develop biomarker hypotheses. Register for this webinar to learn more about our bioinformatics platforms: •Explore how to use sequencing as a tool to gain a deeper understanding of your therapeutic •Review case studies exploring biomarkers of sensitivity and resistance, including our newly included AML NGS datasets •Investigate gene signatures and biomarker pathways to discover new hypotheses

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (48)
Subscribers (2562)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.